Results 31 to 40 of about 117 (84)

Efficacy profile of the CYD-TDV dengue vaccine revealed by Bayesian survival analysis of individual-level phase III data

eLife, 2021
Background: Sanofi-Pasteur’s CYD-TDV is the only licensed dengue vaccine. Two phase three trials showed higher efficacy in seropositive than seronegative recipients.
Daniel J Laydon, Ilaria Dorigatti, Wes R Hinsley, Gemma Nedjati-Gilani, Laurent Coudeville, Neil M Ferguson   +5 more
doaj   +1 more source

Safety and immunogenicity of a tetravalent dengue vaccine (CYD-TDV) in HIV-positive adults aged 18–50 years in Brazil: Results from a phase II, randomized, observer-blind, placebo-controlled trial

Human Vaccines & Immunotherapeutics
Dengue is a common arboviral infection that poses a serious health concern worldwide, including Latin America. Our study assessed the safety and immunogenicity of CYD-TDV, a recombinant, live-attenuated, tetravalent dengue vaccine, among HIV-infected ...
Ana Perroud, José Valdez Ramalho Madruga, Luis Fernandes, Kleber Luz, Nemanja Lukic, Sophie Bourée, Martin Sanchez-Ruiz, Fabiana Pegoraro, Celine Petit, Betzana Zambrano, Gustavo Dayan   +10 more
doaj   +1 more source

Optimal Control of Dengue Transmission with Vaccination

Mathematics, 2021
Dengue disease is caused by four serotypes of the dengue virus: DEN-1, DEN-2, DEN-3, and DEN-4. The chimeric yellow fever dengue tetravalent dengue vaccine (CYD-TDV) is a vaccine currently used in Thailand.
Anusit Chamnan, Puntani Pongsumpun, I-Ming Tang, Napasool Wongvanich   +3 more
doaj   +1 more source

Profiling an Enhanced IL‐6 Expression Distinguishes Host Susceptibility to Primary and Secondary Infections of the Dengue Virus in an Ex Vivo Whole‐Blood Coculture Model

Journal of Tropical Medicine, Volume 2026, Issue 1, 2026.
Dengue virus (DENV) infection can potentially lead to severe dengue disease due to the risk of antibody‐dependent enhancement. This study reports a comparative analysis of the host cytokine/chemokine response triggered by primary and secondary DENV infections using an artificial ex vivo whole‐blood coculture model to simulate viremia during the acute ...
Josephine Diony Nanda, Ming-Kai Jhan, Rahmat Dani Satria, Yung-Ting Wang, Tzong-Shiann Ho, Herdiantri Sufriyana, Emily Chia-Yu Su, Chiou-Feng Lin, Biswadeep Das   +8 more
wiley   +1 more source

Post-marketing safety profile of dengue vaccines CYD-TDV and TAK-003: analysis of adverse event reports from a European database

Frontiers in Pharmacology
IntroductionDengue is one of the major global public health burden, particularly in endemic regions. CYD-TDV and TAK-003 are the currently licensed live attenuated tetravalent dengue vaccines, differing in serostatus indication, age range, and ...
Viviana Maria Gianguzzo, Michelangelo Rottura, Federica Maria Sacco, Matthew Gavino Donadu, Giuseppina Sanna, Natasha Irrera, Egidio Imbalzano, Vincenzo Arcoraci, Giuseppinella Melita, Ylenia Marino, Sara Manti, Giovanni Pallio   +11 more
doaj   +1 more source

Silica Nanoparticles as Multifunctional Platforms for Vaccine Delivery and Immune Modulation in Infectious Diseases

Advanced NanoBiomed Research, Volume 5, Issue 12, December 2025.
Overview of the use of silica nanoparticles in vaccines against pathogens. Different kinds of vaccines against infectious diseases are currently using solid or mesoporous silica nanoparticles in their formulation. Silica microparticles and nanoparticles (SiNPs) have been studied as vehicles for vaccines.
Noe Juvenal Mendoza‐Ramírez, Julio García‐Cordero, Gabriela Navarro‐Tovar, Leticia Cedillo‐Barrón   +3 more
wiley   +1 more source

Vaccine development for mosquito-borne viral diseases

Frontiers in Immunology, 2023
Mosquito-borne viral diseases are a group of viral illnesses that are predominantly transmitted by mosquitoes, including viruses from the Togaviridae and Flaviviridae families.
Zhiwei Huang, Yuxuan Zhang, Hongyu Li, Jiajie Zhu, Wanchen Song, Keda Chen, Yanjun Zhang, Yongliang Lou   +7 more
doaj   +1 more source

Discovery of a Novel Non‐Nucleoside Inhibitor of RNA‐Dependent RNA Polymerase Against Dengue Virus

MedComm, Volume 6, Issue 12, December 2025.
PN‐1, a novel non‐nucleoside inhibitor of the dengue virus RNA‐dependent RNA polymerase (RdRp), was identified from Panax notoginseng. This compound selectively targets the DENV‐2 NS5 RdRp, inducing conformational changes that inhibit enzymatic activity, thereby suppressing DENV replication both in vitro and in vivo.
Xue‐Mei He, Li‐Fang Zou, Jing‐Tao Yu, Tang‐Jia Yang, Zi‐Bin Lu, Hui‐Hui Cao, Wen Li, Bing Chen, Wei Zhao, Jian‐Ping Zuo, Lin‐Zhong Yu, Jun‐Shan Liu   +11 more
wiley   +1 more source

A recombinant live attenuated tetravalent vaccine for the prevention of dengue

Expert Review of Vaccines, 2017
Introduction: Dengue is an important and still growing public health problem associated with substantial morbidity, as well as significant social and economic impact.
Bruno Guy, Fernando Noriega, R. Leon Ochiai, Maïna L’azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino, Nicholas Jackson   +9 more
doaj   +1 more source

Human T Cell Responses to Flavivirus Vaccines

European Journal of Immunology, Volume 55, Issue 8, August 2025.
This review summarises current knowledge of T cell responses induced by flavivirus vaccines being licensed or under development. Existing vaccines against flaviviruses have been developed and analysed primarily in the context of antibody responses, while the role of T cells in contributing to immunity against flaviviruses is less studied.
David Wullimann, Hans‐Gustaf Ljunggren
wiley   +1 more source